← Back to Clinical Trials
Recruiting NCT07383948

NCT07383948 Resilient Families Feasibility Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07383948
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Parents
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-04-01
Primary Completion 2027-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Resilient Families (R-FAM)Educational Resources & Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-04-01 with a primary completion date of 2027-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to test the feasibility and acceptability of a dyadic, resiliency intervention ("Resilient Families;" R-FAM) that aims to reduce emotional distress and improve relationships among parents in the Neonatal Intensive Care Unit (NICU). To achieve this goal, the investigators are developing a randomized control trial where patients will be randomized to either the R-FAM condition or a minimally enhanced usual control (MEUC), which includes resources on parent mental health and coping in the NICU.

Eligibility Criteria

Inclusion Criteria: * Adult parent/legal guardian (and/or their partner) of a baby admitted to the NICU within past week (age ≥ 18) * Currently in an intimate relationship and will live with baby after NICU discharge * At least one dyad member is emotionally distressed (GAD\>=10 or PHQ \>= 10) * English fluency/literacy * Ability and willingness to participate via live video Exclusion Criteria: * Baby is expected to pass away (as determined by medical team) * Current, untreated psychosis or substance dependence/abuse * Current self-report of suicidal ideation

Contact & Investigator

Central Contact

Victoria A Grunberg, PhD

✉ vgrunberg@mgh.harvard.edu

📞 617-643-4133

Principal Investigator

Victoria A Grunberg, PhD

PRINCIPAL INVESTIGATOR

Massachusetts General Hospital

Frequently Asked Questions

Who can join the NCT07383948 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Parents. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07383948 currently recruiting?

Yes, NCT07383948 is actively recruiting participants. Contact the research team at vgrunberg@mgh.harvard.edu for enrollment information.

Where is the NCT07383948 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT07383948 clinical trial?

NCT07383948 is sponsored by Massachusetts General Hospital. The principal investigator is Victoria A Grunberg, PhD at Massachusetts General Hospital. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology